nature.com

Comprehensive analysis of kinase inhibitor selectivity - Nature Biotechnology

  • ️Zarrinkar, Patrick P
  • ️Sun Oct 30 2011
  • Resource
  • Published: 30 October 2011

Nature Biotechnology volume 29, pages 1046–1051 (2011)Cite this article

Subjects

Abstract

We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome. Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend. The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compounds tested. Analysis of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily. The data set suggests compounds to use as tools to study kinases for which no dedicated inhibitors exist. It also provides a foundation for further exploring kinase inhibitor biology and toxicity, as well as for studying the structural basis of the observed interaction patterns. Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

References

  1. Bain, J., McLauchlan, H., Elliott, M. & Cohen, P. The specificities of protein kinase inhibitors: an update. Biochem. J. 371, 199–204 (2003).

    Article  CAS  Google Scholar 

  2. Bantscheff, M. et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035–1044 (2007).

    Article  CAS  Google Scholar 

  3. Fabian, M.A. et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23, 329–336 (2005).

    Article  CAS  Google Scholar 

  4. Melnick, J.S. et al. An efficient rapid system for profiling the cellular activities of molecular libraries. Proc. Natl. Acad. Sci. USA 103, 3153–3158 (2006).

    Article  CAS  Google Scholar 

  5. Patricelli, M.P. et al. Functional interrogation of the kinome using nucleotide acyl phosphates. Biochemistry 46, 350–358 (2007).

    Article  CAS  Google Scholar 

  6. Fedorov, O. et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc. Natl. Acad. Sci. USA 104, 20523–20528 (2007).

    Article  CAS  Google Scholar 

  7. Karaman, M.W. et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127–132 (2008).

    Article  CAS  Google Scholar 

  8. Bamborough, P., Drewry, D., Harper, G., Smith, G.K. & Schneider, K. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. J. Med. Chem. 51, 7898–7914 (2008).

    Article  CAS  Google Scholar 

  9. Posy, S.L. et al. Trends in kinase selectivity: insights for target class-focused library screening. J. Med. Chem. 54, 54–66 (2011).

    Article  CAS  Google Scholar 

  10. Metz, J.T. et al. Navigating the kinome. Nat. Chem. Biol. 7, 200–202 (2011).

    Article  CAS  Google Scholar 

  11. Liu, Y. & Gray, N.S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2, 358–364 (2006).

    Article  CAS  Google Scholar 

  12. Manning, G., Whyte, D.B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912–1934 (2002).

    Article  CAS  Google Scholar 

  13. Zarrinkar, P.P. et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 114, 2984–2992 (2009).

    Article  CAS  Google Scholar 

  14. Ohren, J.F. et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat. Struct. Mol. Biol. 11, 1192–1197 (2004).

    Article  CAS  Google Scholar 

  15. Buchanan, S.G. et al. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Mol. Cancer Ther. 8, 3181–3190 (2009).

    Article  CAS  Google Scholar 

  16. Wood, E.R. et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 64, 6652–6659 (2004).

    Article  CAS  Google Scholar 

  17. Simard, J.R. et al. Fluorophore labeling of the glycine-rich loop as a method of identifying inhibitors that bind to active and inactive kinase conformations. J. Am. Chem. Soc. 132, 4152–4160 (2010).

    Article  CAS  Google Scholar 

  18. Wodicka, L.M. et al. Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem. Biol. 17, 1241–1249 (2010).

    Article  CAS  Google Scholar 

  19. Carlomagno, F. et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 23, 6056–6063 (2004).

    Article  CAS  Google Scholar 

  20. Goldstein, D.M., Gray, N.S. & Zarrinkar, P.P. High-throughput kinase profiling as a platform for drug discovery. Nat. Rev. Drug Discov. 7, 391–397 (2008).

    Article  CAS  Google Scholar 

  21. Kwiatkowski, N. et al. Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function. Nat. Chem. Biol. 6, 359–368 (2010).

    Article  CAS  Google Scholar 

  22. Deng, X. et al. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat. Chem. Biol. 7, 203–205 (2011).

    Article  CAS  Google Scholar 

  23. Hasinoff, B.B. & Patel, D. The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro. Toxicol. Appl. Pharmacol. 249, 132–139 (2010).

    Article  CAS  Google Scholar 

  24. Huang, D., Zhou, T., Lafleur, K., Nevado, C. & Caflisch, A. Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis. Bioinformatics 26, 198–204 (2010).

    Article  Google Scholar 

  25. Olaharski, A.J. et al. Identification of a kinase profile that predicts chromosome damage induced by small molecule kinase inhibitors. PLOS Comput. Biol. 5, e1000446 (2009).

    Article  Google Scholar 

  26. Yang, X. et al. Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data. J. Biomed. Inform. 43, 376–384 (2010).

    Article  CAS  Google Scholar 

  27. Remsing Rix, L.L. et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 23, 477–485 (2009).

    Article  CAS  Google Scholar 

  28. Knight, Z.A., Lin, H. & Shokat, K.M. Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer 10, 130–137 (2010).

    Article  CAS  Google Scholar 

  29. Miduturu, C.V. et al. High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors. Chem. Biol. 18, 868–879 (2011).

    Article  CAS  Google Scholar 

  30. Cortes, J. et al. AC220, a potent, selective, second generation FLT3 receptor tyrosine kinase (RTK) inhibitor, in a first-in-human (FIH) phase I clinical trial. Blood (ASH Annual Meeting Abstracts) 114, Abstract 636 (2009).

    Google Scholar 

Download references

Acknowledgements

We thank W. Wierenga for critical reading of the manuscript, A. Torres, G. Riggs and M. Costa for compound management, M. Floyd and L. Ramos for expert molecular biology technical assistance, C. Shewmaker and J. Lowe for expert compound screening technical assistance, R. Faraoni for advice on compound synthesis and D. Jones for assistance preparing Figure 4.

Author information

Author notes

  1. Mindy I Davis, Jeremy P Hunt, Pietro Ciceri, Lisa M Wodicka, Gabriel Pallares, Daniel K Treiber & Patrick P Zarrinkar

    Present address: Present addresses: National Institutes of Health, Bethesda, Maryland, USA (M.I.D.), KINOMEscan Division of DiscoveRx Corporation, San Diego, California, USA (J.P.H., P.C., L.M.W., G.P., D.K.T.) and Blueprint Medicines Corporation, San Diego, California, USA (P.P.Z.).,

  2. Mindy I Davis, Jeremy P Hunt, Sanna Herrgard and Pietro Ciceri: These authors contributed equally to this work.

Authors and Affiliations

  1. Ambit Biosciences, San Diego, California, USA

    Mindy I Davis, Jeremy P Hunt, Sanna Herrgard, Pietro Ciceri, Lisa M Wodicka, Gabriel Pallares, Michael Hocker, Daniel K Treiber & Patrick P Zarrinkar

Authors

  1. Mindy I Davis

    You can also search for this author in PubMed Google Scholar

  2. Jeremy P Hunt

    You can also search for this author in PubMed Google Scholar

  3. Sanna Herrgard

    You can also search for this author in PubMed Google Scholar

  4. Pietro Ciceri

    You can also search for this author in PubMed Google Scholar

  5. Lisa M Wodicka

    You can also search for this author in PubMed Google Scholar

  6. Gabriel Pallares

    You can also search for this author in PubMed Google Scholar

  7. Michael Hocker

    You can also search for this author in PubMed Google Scholar

  8. Daniel K Treiber

    You can also search for this author in PubMed Google Scholar

  9. Patrick P Zarrinkar

    You can also search for this author in PubMed Google Scholar

Contributions

M.I.D. coordinated development of the assay panel, J.P.H. developed technology to enhance the efficiency of compound screening, S.H. analyzed data, M.I.D., J.P.H., P.C. and L.M.W. developed binding assay technology and performed assay development, G.P. coordinated and executed the measurement of Kd values, M.H. synthesized compounds, D.K.T. conceived the technology, designed assay development strategies, and supervised technology and assay development, S.H. and D.K.T. contributed to preparation of the manuscript, P.P.Z. designed the study, supervised the project, analyzed data and wrote the manuscript.

Corresponding authors

Correspondence to Daniel K Treiber or Patrick P Zarrinkar.

Ethics declarations

Competing interests

All authors are former or current employees of Ambit Biosciences and were employed by Ambit during the course of the project described in the manuscript. J.P.H., P.C., L.M.W., G.P. and D.K.T. are current employees of Discoverx Corp. Discoverx has acquired the technology used for the project from Ambit Biosciences.

Supplementary information

Supplementary Text and Figures

Supplementary Table 2 and Supplementary Figures 1–3 (PDF 2922 kb)

Supplementary Table 1

List of 442 kinase domains in the assay panel and their calculated kinase selectivity scores. (XLS 92 kb)

Supplementary Table 3

Compounds tested, their primary targets, and comparison of published and measured activities. (XLS 39 kb)

Supplementary Table 4

Binding results (Kd's in nM) for 72 inhibitors vs 442 kinase assays. Blank fields indicate combinations that were tested, but for which binding was weak (Kd > 10 uM), or not detected in a 10 uM primary screen. (XLS 297 kb)

Supplementary Table 5

Compound selectivity scores. (XLS 31 kb)

About this article

Cite this article

Davis, M., Hunt, J., Herrgard, S. et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 29, 1046–1051 (2011). https://doi.org/10.1038/nbt.1990

Download citation

  • Received: 10 May 2011

  • Accepted: 30 August 2011

  • Published: 30 October 2011

  • Issue Date: November 2011

  • DOI: https://doi.org/10.1038/nbt.1990

This article is cited by

Associated content